Area of research
Infectious Diseases · Epidemiology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, Influenza Virus Research Studies, Viral Infections and Vectors, and Immunotherapy and Immune Responses.
Reinforcement Learning for Adaptive Resource Scheduling in Complex System Environments
mRNA vaccines: A promising platform for safer, more effective next-generation Orthopoxvirus immunization
A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates
A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates.
Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies.
Novel (Z)/(E)-1,2,4-triazole derivatives containing oxime ether moiety as potential ergosterol biosynthesis inhibitors: design, preparation, antifungal evaluation, and molecular docking
Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants.
A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants.
Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants
Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants.
A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants.
Protective Zika vaccines engineered to eliminate enhancement of dengue infection via immunodominance switch.
Distinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice.
Design, synthesis, antifungal evaluation, and molecular docking of novel 1,2,4-triazole derivatives containing oxime ether and cyclopropyl moieties as potential sterol demethylase inhibitors
Publisher Correction: A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS
Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2
Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2.
Structures of the four Ig-like domain LILRB2 and the four-domain LILRB1 and HLA-G1 complex.
Molecular basis of EphA2 recognition by gHgL from gammaherpesviruses.
Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry.
Novel carboxylated pyrroline-2-one derivatives bearing a phenylhydrazine moiety: Design, synthesis, antifungal evaluation and 3D-QSAR analysis
Molecular Basis of Arthritogenic Alphavirus Receptor MXRA8 Binding to Chikungunya Virus Envelope Protein
Structural insight into RNA synthesis by influenza D polymerase.
Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus.
The FG Loop of PD-1 Serves as a “Hotspot” for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy
Avian-to-Human Receptor-Binding Adaptation of Avian H7N9 Influenza Virus Hemagglutinin